PARP inhibitors: pitfalls and promises.

doi:10.1016/S1470-2045(13)70276-6

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

PARP inhibitors: pitfalls and promises.

The Lancet. Oncology - 1 Aug 2013

Infante Jeffrey R, Burris Howard A

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein
Share to Indazoles
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Recurrence, Local

Share to Neoplasms

Share to Piperidines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Open in PubMed

Identifiers

PMID: 23810789
DOI: 10.1016/S1470-2045(13)70276-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP inhibitors: pitfalls and promises.PMID 23810789Read ↗

PARP inhibitors: the story is still unfolding.Semantic proximity Read ↗

Development of PARP inhibitors: an unfinished story.Semantic proximity Read ↗

PARP inhibitors coming of ageSemantic proximity Read ↗

PARP Inhibition in Cancer: An Update on Clinical DevelopmentSemantic proximity Read ↗

Delving into PARP inhibition from bench to bedside and backSemantic proximity Read ↗

EMBRACing a new PARP inhibitor?Semantic proximity Read ↗

PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?Semantic proximity Read ↗

PARP inhibitors: New partners in the therapy of cancer and inflammatory diseasesSemantic proximity Read ↗

An update on PARP inhibitors—moving to the adjuvant settingSemantic proximity Read ↗

Understanding and overcoming resistance to PARP inhibitors in cancer therapySemantic proximity Read ↗

PARP inhibitorsSemantic proximity Read ↗

PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.